The Insurance Regulatory and Development Authority of India, under the standard health insurance plan Arogya Sanjeevani Policy, has made it mandatory for insurers to offer a sum insured between Rs 50,000 to how many rupees?

The Insurance Regulatory and Development Authority of India, under the standard health insurance plan Arogya Sanjeevani Policy, has made it mandatory for insurers to offer a sum insured between Rs 50,000 to how many rupees? Correct Answer 10 lakh

The correct answer is 10 lakh.

  • The Insurance Regulatory and Development Authority of India (Irdai) has hiked the maximum cover under the standard health insurance plan Arogya Sanjeevani Policy, from Rs 5 lakh earlier to Rs 10 lakh.
  • It has made it mandatory for insurers to offer a sum insured between Rs 50,000 to Rs 10 lakh.
  • Arogya Sanjeevani is a standardized health insurance product that was launched in March 2020.
  • IRDAI is an autonomous, statutory body tasked with regulating and promoting the insurance and re-insurance industries in India.
  • Headquarters - Hyderabad.

Related Questions

IRDAI has issued a circular allowing health and general insurance companies to offer which Policy for a minimum sum insured of Rs 50,000 and maximum sum insured above Rs 5 lakh?
In the question below, are given a statement followed by three courses of actions numbered I, II and III. On the basis of the information given, you have to assume everything in the statement to be true, and then decide which of the suggested courses of action logically follow(s) for pursuing. Statement: India’s pharmaceutical sector is now popping out from a shell and making a remarkable recovery. Actually, it has been facing several regulatory challenges in the forms of a recast of foreign direct investment (FDI) policy, pricing policy in the US generics market, patent protection, regulatory approvals and compulsory licensing. Also limited new product launches in the generics space, GST introduction and higher costs associated with regulatory compliance have hurt the sector. Courses of action: I. The government has been engrossed more in policy making and taking resilient decisions for the concerns of the pharma industry. Recently, the government proposed to introduce a new price index for pharmaceutical products, which would serve as a benchmark for determining prices of all medicines sold in the country. II. Meanwhile, pharma companies’ constant investments in R&D have enabled them to develop a basket of robust products for markets across the world. In international markets, pricing pressure on generics sold in the US has eased and this is likely to support the sector. III. Domestic pharma sales grew to Rs. 10,583 crore in May 2018 from Rs. 9,549 crore in the same month last year. The recent clearance by the US Food and Drug Administration to Sun Pharma’s manufacturing plant at Halol in Gujarat brings to an end a two-year import ban it had imposed on the company over quality issues. This is likely to increase sales for the company.